Latest News

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, presented 1-year primary end point results from the phase 3 DAYBREAK trial.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal wound healing.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

Long-term data from the GLK-202-03 extension study show a sustained 1.9 D improvement in Kmax after a single epithelium-on cross-linking treatment, with no serious or treatment-related adverse events reported.

Arun C. Gulani, MD, introduces a keratoconus classification based on what prevents vision: visual, structural, or salvage.

A solo surgeon explains how automation replaced his front desk, scheduling, and billing staff.

The Wilmer Eye Institute's new Glaucoma Division chief discusses mentoring junior faculty, multicenter trials, and optic nerve regeneration.

September was one of the busiest months of the year in eye care—From ESCRS to Eyecon

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.

Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.